1. Google has experimented expanding DoubleClick to be used for outdoor advertising for the first time:
Many believe this might be a big step in the out-of-home industry.
2.Google has slammed the brakes on its acquisition machine:
Google’s 10Q quarterly earnings report shows the company marked its lowest deal activity, by value, in six years.
3. Stocks fall on China data, but stronger euro zone lifts gloom:
Stocks fell in Europe and Asia on Monday after further evidence of economic slowdown in China, but modest growth in German factory activity slightly brightened the mood:
Stocks fell in Europe and Asia on Monday after further evidence of economic slowdown in China, but modest growth in German factory activity slightly brightened the mood.The index was last down 0.2 percent, with Germany’s DAX .GDAXI up 0.2 percent.
4. Euro zone factory growth remains weak in October despite ECB stimulus: PMI
The European Central Bank’s massive stimulus program has done little to spur manufacturing growth in the euro zone, a survey showed on Monday, as factories again resorted to slashing prices to drum up trade.The October reading of 52.0. has, however, been above the 50 mark that separates growth from contraction for over two years.
5. Oil Price Paradox: Gasoline Could Be Even Cheaper:
The price of gasoline is declining more slowly than oil, illustrating how consumers aren’t fully benefiting from falling commodities prices.
6.Visa Confirms Deal to Buy European Counterpart for $23.4 Billion:
Visa Inc. on Monday confirmed plans to buy its European counterpart Visa Europe for up to €21.2 billion ($23.4 billion) in cash and stock, a deal that would bring Visa’s global operations under one roof.
7. HSBC Reports Sharp Rise in Third-Quarter Profit:
HSBC Holdings PLC on Monday pledged to press on with costs cuts in the coming months as the bank reported a sharp rise in third-quarter profit.
8.Shire to Acquire Dyax for Up to $6.5 Billion:
LONDON—Shire PLC has struck an all-cash deal worth up to $6.5 billion for U.S. biotech Dyax Corp., demonstrating the company’s unwavering focus on midsize acquisitions even as it chases a $30 billion deal for rare disease rival Baxalta Inc.
